Johnson & Johnson (JNJ) Stake Raised by Franklin Street Advisors Inc. NC
Franklin Street Advisors Inc. NC increased its position in Johnson & Johnson (NYSE:JNJ) by 31.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 84,373 shares of the company’s stock after buying an additional 19,947 shares during the period. Johnson & Johnson makes up about 1.8% of Franklin Street Advisors Inc. NC’s investment portfolio, making the stock its 10th largest position. Franklin Street Advisors Inc. NC’s holdings in Johnson & Johnson were worth $9,967,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Marcus Capital LLC boosted its position in Johnson & Johnson by 2.4% in the first quarter. Marcus Capital LLC now owns 21,650 shares of the company’s stock valued at $2,343,000 after buying an additional 500 shares during the last quarter. Baker Ellis Asset Management LLC boosted its position in Johnson & Johnson by 1.0% in the first quarter. Baker Ellis Asset Management LLC now owns 33,655 shares of the company’s stock valued at $3,641,000 after buying an additional 340 shares during the last quarter. NN Investment Partners Holdings N.V. acquired a new position in Johnson & Johnson during the first quarter valued at about $92,331,000. Adell Harriman & Carpenter Inc. boosted its position in Johnson & Johnson by 5.4% in the first quarter. Adell Harriman & Carpenter Inc. now owns 83,918 shares of the company’s stock valued at $9,080,000 after buying an additional 4,292 shares during the last quarter. Finally, Canandaigua National Bank & Trust Co. boosted its position in Johnson & Johnson by 0.3% in the first quarter. Canandaigua National Bank & Trust Co. now owns 97,516 shares of the company’s stock valued at $10,551,000 after buying an additional 291 shares during the last quarter. Hedge funds and other institutional investors own 64.13% of the company’s stock.
Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.88% on Monday, hitting $113.13. The stock had a trading volume of 9,025,708 shares. Johnson & Johnson has a one year low of $94.28 and a one year high of $126.07. The firm’s 50 day moving average is $116.14 and its 200-day moving average is $118.35. The stock has a market capitalization of $307.77 billion, a PE ratio of 19.86 and a beta of 0.75.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 18th. The company reported $1.68 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.66 by $0.02. The firm had revenue of $17.80 billion for the quarter, compared to analyst estimates of $17.71 billion. Johnson & Johnson had a return on equity of 25.30% and a net margin of 22.03%. The company’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same period in the previous year, the company posted $1.49 earnings per share. Equities research analysts expect that Johnson & Johnson will post $6.72 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Shareholders of record on Tuesday, November 22nd will be issued a dividend of $0.80 per share. The ex-dividend date is Friday, November 18th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.29. This represents a $3.20 annualized dividend and a yield of 2.80%. Johnson & Johnson’s payout ratio is currently 56.64%.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another domain, it was stolen and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2016/11/28/johnson-johnson-jnj-stake-raised-by-franklin-street-advisors-inc-nc.html.
JNJ has been the subject of several recent analyst reports. Leerink Swann reissued a “buy” rating on shares of Johnson & Johnson in a research note on Sunday, September 11th. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $133.00 price target for the company in a research note on Tuesday, September 13th. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 price target for the company in a research note on Monday, August 22nd. Deutsche Bank AG reissued a “buy” rating and issued a $142.00 price target on shares of Johnson & Johnson in a research note on Friday, August 19th. Finally, Argus restated a “buy” rating and issued a $145.00 price objective on shares of Johnson & Johnson in a report on Friday, October 21st. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $121.02.
In other Johnson & Johnson news, Director Charles Prince bought 875 shares of Johnson & Johnson stock in a transaction on Friday, October 21st. The shares were purchased at an average cost of $114.11 per share, for a total transaction of $99,846.25. Following the completion of the acquisition, the director now owns 26,520 shares in the company, valued at approximately $3,026,197.20. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.11% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.